Tratamiento con eritropoyetina recombinante humana, hipertrofia ventricular izquierda y balance beneficio riesgo en la ERC-3b

by Jorge F Pérez-Oliva Díaz, Martha Casanova González, Orosmán Cuesta Panaco, Osniel Bencomo Rodríguez, Beatriz López Tórres, Claudio González, Liván Cruz Benítez, Idrian García García, Ángela D Tuero Iglesias, Carmen M Valenzuela Silva, Pedro A López Saura

Clinical evaluation of patients with benign prostatic hyperplasia, treated with the natural product Calprost®: a randomized, controlled study

by Magnelis Machado-Leiva, Daise Jiménez-Rodríguez, Tatiana Festary-Casanovas, Deydree C. Silveira-Pacheco, Emilio S. Barroso-de la Cruz, Mariela Suárez-Reyes, Genma Salas-Cruz, Haydee Wong-Arocha, Roberto Fernández-Viera, Ángela D. Tuero-Iglesias, René Delgado-Hernández, Idrian García-García, Calprost Study Group
Published 2016-10-01